Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China.
Drug Metab Dispos. 2010 Jun;38(6):973-80. doi: 10.1124/dmd.109.030734. Epub 2010 Feb 22.
Daphnetin has been developed as an oral medicine for treatment of coagulation disorders and rheumatoid arthritis in China, but its in vitro metabolism remains unknown. In the present study, the UDP-glucuronosyltransferase (UGT) conjugation pathways of daphnetin were characterized. Two metabolites, 7-O-monoglucuronide daphnetin (M-1) and 8-O-monoglucuronide daphnetin (M-2), were identified by liquid chromatography/mass spectrometry and NMR when daphnetin was incubated, respectively, with liver microsomes from human (HLM), rat (RLM), and minipig (PLM) and human intestinal microsomes (HIM) in the presence of UDP-glucuronic acid. Screening assays with 12 human recombinant UGTs demonstrated that the formations of M-1 and M-2 were almost exclusively catalyzed by UGT1A9 and UGT1A6, whereas M-1 was formed to a minor extent by UGT1A3, 1A4, 1A7, 1A8, and 1A10 at a high substrate concentration. Kinetics studies, chemical inhibition, and correlation analysis were used to demonstrate that human UGT1A9 and UGT1A6 were major isoforms involved in the daphnetin glucuronidations in HLM and HIM. By in vitro-in vivo extrapolation of the kinetic data measured in HLM, the hepatic clearance and the corresponding hepatic extraction ratio were estimated to be 19.3 ml/min/kg b.wt. and 0.93, respectively, suggesting that human clearance of daphnetin via the glucuronidation is extensive. Chemical inhibition of daphnetin glucuronidation in HLM, RLM, and PLM showed large species differences although the metabolites were formed similarly among the species. In conclusion, the UGT conjugation pathways of daphnetin were fully elucidated and its C-8 phenol group was more selectively catalyzed by UGTs than by the C-7 phenol.
瑞香素已被开发为一种口服药物,用于治疗中国的凝血障碍和类风湿性关节炎,但它的体外代谢仍不清楚。在本研究中,表征了瑞香素的 UDP-葡糖醛酸基转移酶(UGT)结合途径。当瑞香素分别与人(HLM)、大鼠(RLM)和小型猪(PLM)的肝微粒体以及人肠微粒体(HIM)在 UDP-葡糖醛酸存在下孵育时,通过液质联用和 NMR 鉴定出两种代谢产物,7-O-单葡糖苷瑞香素(M-1)和 8-O-单葡糖苷瑞香素(M-2)。用 12 个人重组 UGT 的筛选试验表明,M-1 和 M-2 的形成几乎完全由 UGT1A9 和 UGT1A6 催化,而在高底物浓度下,M-1 由 UGT1A3、1A4、1A7、1A8 和 1A10 少量形成。动力学研究、化学抑制和相关分析表明,人 UGT1A9 和 UGT1A6 是 HLM 和 HIM 中瑞香素葡糖苷化的主要同工酶。通过在 HLM 中测量的动力学数据的体外-体内外推,估计肝清除率和相应的肝提取率分别为 19.3 ml/min/kg b.wt. 和 0.93,表明人通过葡糖苷酸化清除瑞香素的程度很高。HLM、RLM 和 PLM 中瑞香素葡糖苷化的化学抑制显示出很大的种间差异,尽管在这些物种中代谢产物的形成相似。总之,瑞香素的 UGT 结合途径已被充分阐明,其 C-8 酚基比 C-7 酚基更被 UGTs 选择性催化。